Class Action Suit Filed Against KalaBios

Goldberg Law PC has announced a class action suit against KaloBios Pharmaceuticals, charging that the company, until recently headed by industry “bad boy” Martin Shkreli, may have provided “misleading information” to investors.

Shrekli was indicted on securities fraud charges several days before Christmas.

KaloBios thus becomes the second drugmaker with ties to Shkreli to come under pressure since the indictment. The first was Turing Pharmaceuticals, another company headed by the former hedge fund manager.

Turing and its CEO were widely criticized for jacking up the price of the 62-year-old anti-parasitic drug Daraprim (pyrimethamine) from $13.50 to $700 a tablet shortly after acquiring marketing rights in August 2015.

According to reports, KaloBios had considered raising prices of another parasitic infection drug, benznidazole, to around $1,000 per pill.

On December 29, KaloBios filed a voluntary petition for Chapter 11 bankruptcy protection in a US bankruptcy court for the District of Delaware. A day later, the drugmaker was informed by the NASDAQ stock market that its shares would be delisted.

The company’s appeal against the decision to delist will be heard by a NASDAQ appeal panel in late February.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.